The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 935
Zhao, P., Zhang, S., Wang, P., Zhong, H., Chen, Y., Zhang, D., & Chen, Z. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114814 · Cited by 4
Zhou, K., Ebben, L., Dhakal, B., & Vallatharasu, Y. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00748 · Cited by 4
Iannantuono, G. M., Giovagnoli, T., Mastrantoni, L., Gyawali, B., Floudas, C. S., Sganga, S., Giannarelli, D., Filetti, M., Spinazzola, A., Bianco, F. L., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106065 · Cited by 4
Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches
Kidwai, N., Chen, M. F., Postow, M. A., Hassel, J. C., & Callahan, M. K. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432462 · Cited by 5
Self-citationSwords, E., Kennedy, B. N., & Tonelotto, V. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466896 · Cited by 4
Noguchi, T., Ariga, S., Moku, R., Kikuchi, J., Amano, T., Maeda, T., Ishikawa, K., Maeda, T., Shiiya, A., Goda, T., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00437 · Cited by 4
Luo, L., Wang, B., Li, Q., Zhang, L., Li, C., Jin, A., Qi, H., & Tang, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113869 · Cited by 4
Luckett, T., Ng, C., Lai-Kwon, J. E., Kee, D., Mulhern, B. J., & Joshua, A. M. (2025) · BMC Cancer · doi:10.1186/s12885-025-14368-6 · Cited by 4
Self-citationGrigoruţă, M., Kong, X., & Qin, Y. W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145137 · Cited by 4
McCall, T. F., Sawyer, E. J., Darnell, J., Hirsch, M. L., & Bower, J. J. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201020 · Cited by 4
Immunologic specificity in glioblastoma: Antigen discovery and translational implications
Hill, C. M., Wang, A. Z., Hsueh, B., Ramirez, R., Sherpa, N. D., Costa, M. A., Williams, O., Mao, L., & Dunn, G. P. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf028 · Cited by 5
Giacomo, A. M. D., Simonelli, M., Losurdo, A., Spiliopoulou, P., D’Alonzo, V., Amato, G., Valente, M., Barcenilla, H., Johnsson, A., González, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77358-7 · Cited by 4
Autoimmune skin disease pathogenesis: a chronological immune cascade and multi-hit model
Chen, J., Yin, H., Li, S., & Li, C. (2026) · Immunity & Inflammation · doi:10.1007/s44466-025-00017-x · Cited by 5
Vandekerckhove, L., Fox, J., Mora‐Peris, B., Navarro, J., Allard, S. D., Uriel, A. J., Guillen, S. M., Boffito, M., Post, F. A., Estrada, V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68833-2 · Cited by 5
The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma
Robat-Jazi, B., Lorestani, P., Nejati, N., Ebrahimi, E., Habibi, M. A., Ahmadpour, M., Jokar-Derisi, A., Karimizadeh, Z., Bagheri, K., & Ahmadpour, S. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02057-y · Cited by 4
Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma
Yang, K., & Wu, D. (2026) · Melanoma Research · doi:10.1097/cmr.0000000000001089 · Cited by 4
Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
Piperno‐Neumann, S., Angi, M., Ascierto, P. A., Baurain, J., Burgmans, M. C., Cassoux, N., Coupland, S. E., Dendale, R., Fortuna, A. R. F. P., Gastaud, L., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106888 · Cited by 4
Self-citationPereira, P. M., Luís, A., Passos, M. J., & Gouveia, E. J. (2022) · Ocular Oncology and Pathology · doi:10.1159/000527445 · Cited by 4
Nejadghaderi, S. A., Balibegloo, M., Noori, M., Fayyaz, F., Saghazadeh, A., & Rezaei, N. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2183847 · Cited by 4
Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma – A Single Center Analysis
GLASER, N., Petzold, A., Wessely, A., Kaufmann, M. D., Koch, E. A. T., Knorr, H. L. J., Voskens, C., Heppt, M. V., Berking, C., & Erdmann, M. (2023) · Anticancer Research · doi:10.21873/anticanres.16646 · Cited by 4
Identifying biomarkers and novel therapeutic targets in uveal melanoma
Wessely, A., Koch, E. A. T., Vera, J., Berking, C., & Heppt, M. V. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15225 · Cited by 4
Lu, C., Zou, L., Wang, Q., Sun, M., Shi, T., Shuang, X., Meng, F., & Du, J. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2024.10431 · Cited by 4
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy
Knight, A. D., & Luke, J. J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01551-4 · Cited by 4
Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting
Stålhammar, G., Vishnevskia‐Dai, V., Verdijk, R. M., & Moulin, A. (2024) · Ocular Oncology and Pathology · doi:10.1159/000541016 · Cited by 4
Alam, B., Akbari, A. R., Ageed, A., & Duffy, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030885 · Cited by 4
Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
Momoi, Y., Kumagai, S., & Nishikawa, H. (2025) · International Immunology · doi:10.1093/intimm/dxaf020 · Cited by 5
Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors
Devaux, A., & Baurain, J.-F. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000821 · Cited by 4
Self-citationEnd-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study
van Breeschoten, J., Ismail, R. K., Wouters, M. W. J. M., Hilarius, D. L., de Wreede, L. C., Haanen, J. B. A. G., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., et al. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00061 · Cited by 4
Sánchez, J., Nicolini, V., Fahrni, L., Waldhauer, I., Walz, A., Jamois, C., Fowler, S. C., Simon, S., Klein, C., Umaña, P., et al. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00755-5 · Cited by 4
Reiter, S., Schroeder, C., Broche, J., Sinnberg, T. W., Bonzheim, I., Süßkind, D., Flatz, L., & Forschner, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167791 · Cited by 4
Chandrasekhar, S. A., Perez, M. C., Niaz, Z., Ekram, J., Lal, N., Koly, S., Cao, B., Zager, J. S., & Alomar, M. (2024) · Cancer Control · doi:10.1177/10732748241246898 · Cited by 4
Investigational bispecific antibodies for the treatment of rheumatoid arthritis
Venetsanopoulou, A. I., Voulgari, P. V., & Drosos, A. A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2351507 · Cited by 4
Boe, M., Vicari, S., Boccatonda, A., & Piscaglia, F. (2024) · Journal of Ultrasound · doi:10.1007/s40477-024-00909-5 · Cited by 3
Helf, C., & Kähler, K. C. (2024) · Clinical and Experimental Dermatology · doi:10.1093/ced/llae427 · Cited by 3
Immunotherapy in Ophthalmic Oncology: Current Trends and Future Directions
Masalkhi, M., Wahoud, N., Moran, B., & Elhassadi, E. (2025) · Journal of Clinical & Translational Ophthalmology · doi:10.3390/jcto3010001 · Cited by 3
Ocular cancer: Advances in diagnostic research
Shah, H. V., Ansari, M., Shinde, U. A., & Singh, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33849-6.00004-0 · Cited by 3
Bai, J., Wan, Z., Wu, Z., & Peng, Q. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1683864 · Cited by 3
Development of a PRAME pMHC targeted T cell engager for solid tumor therapy
Skrzypczynska, K. M., Schimert, K. I., Stephenson, H. T., Mah, I. K., Mortenson, D. E., Boyd, K. L., Hardman, T., Novikov, N. Y., Seto, E., Lu, S., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2563773 · Cited by 3
Pánczél, G., Horváth, P., Temaj, E., Czirbesz, K., Kispál, M. T., Fröhlich, G., & Balatoni, T. (2025) · Cancers · doi:10.3390/cancers17213521 · Cited by 3
Kalkavan, H., Scheulen, M. E., Kämpgen, E., Keilholz, U., Heinzerling, L., Lueong, S., Hlinka, A., Gromke, T., Ochsenreither, S., Hilger, R. A., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114045 · Cited by 3
Self-citationTebentafusp in Metastatic Uveal Melanoma: A Meta-analysis
Saldanha, E. F., Noronha, M. M., Reis, P. C. A., Passos, P. R. C., Filho, V. O. C., Cappellaro, A. P., de Almeida, L. F. C., Maselli-Schoueri, J. H., Lopes, C. D. H., Leite, L. F., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01187-9 · Cited by 3
Exploring copper metabolism and cuproptosis, and their implications in ocular diseases
Xiong, X., Li, Q., Zhang, Y., Liu, P., Pan, Y., & Song, Q. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178472 · Cited by 3
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers
Xu, M., Barakzai, S., Kumar, R., Veillard, I. E., Kim, E., Bregar, A. J., Eisenhauer, E. L., Penson, R. T., Bouberhan, S., Filipi, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02505-3 · Cited by 3
Shatnawi, R., Al-Hyari, A., Al-Latayfeh, M., Abu‐Ain, M., Shatnawi, H., Shatnawi, Y., & Yousef, Y. A. (2025) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2025.10.3.759-768 · Cited by 3
DNA-Damaging Agents Induce PD-L1 Expression through the Src-STAT1-IRF1 Pathway
Suzuki, Y., Nishibu, S., Nohara, A., Onuma, I., Zhou, Y., Sakurai, H., & Yokoyama, S. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00610 · Cited by 3
Liquid biopsies in precision oncology for older adults with cancer
Zhao, Y., Herrera-Caceres, J. O., Nobes, J. H., Lyu, Z., Vetter, M. H. F., Falandry, C., Goede, V., Neuendorff, N. R., Loh, K. P., Canin, B. E., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01285-5 · Cited by 3
Independent validation of time to treatment as a prognostic factor in uveal melanoma
Moghadam, A., Gill, V., Sabazade, S., Hagström, A., & Stålhammar, G. (2026) · BMC Cancer · doi:10.1186/s12885-026-15775-z · Cited by 3
Yang, L., Zhang, C., Zhang, Z., Yao, S., Shen, J., Zhang, Z., Xiao, Z., Wang, S., & Wu, Z. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07887-8 · Cited by 3
Lasagna, A., Re, M. D., Danesi, R., Andreoni, M., Tessitore, D., Maïo, M. D., Silvestris, N., & Pedrazzoli, P. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105253 · Cited by 4
Xu, Y., Wang, F., Liu, W., Lin, R., Liu, C., Zhao, Q., He, G., Yuan, G., Yin, W., Yu, F., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-026-02077-z · Cited by 4
Five-year survival with tebentafusp in metastatic uveal melanoma
Piperno‐Neumann, S., Rutkowski, P., Hassel, J. C., Butler, M. O., Schlaak, M. S., Sullivan, R. J., Dummer, R., Kirkwood, J. M., Sacco, J. J., Shoushtari, A. N., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.05.695 · Cited by 3
Self-citationMelanoma - Standard of Care, Challenges, and Updates in Clinical Research
Maciá, S., & Castañón, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100843 · Cited by 3
Nouvelles AMM : le tebentafusp dans le mélanome uvéal métastatique HLA A*02:01 positif
Gaillard, A., Matet, A., & Rodrigues, M. J. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.10.001 · Cited by 3
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Fahmy, L. M., Schreidah, C. M., McDonnell, D. E., Carvajal, R. D., MAGRO, C. M. J., & Geskin, L. J. (2024) · Dermatology Online Journal · doi:10.5070/d329662993 · Cited by 3
Self-citationSuwajanakorn, D., Lane, A. M., Go, A. K., Hartley, C. D., Oxenreiter, M. M., Wu, F., Gragoudas, E. S., Sullivan, R. J., Montazeri, K., & Kim, I. K. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000971 · Cited by 3
Self-citationZhao, M., Yu, Y., & Song, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-59827-5 · Cited by 3
Top advances of the year: Melanoma
Khattak, M. A., & Luke, J. J. (2024) · Cancer · doi:10.1002/cncr.35354 · Cited by 3
Beylergil, V., Collins, L. E., Schwartz, L. H., Eche, T., Zhao, B., Champiat, S., Carvajal, R. D., Abedin, S. E., & Dercle, L. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115386 · Cited by 3
Self-citationPowell, T., Karuppiah, V., Shaikh, S. A., Pengelly, R., Mai, N., Barnbrook, K., Sharma, A. K., Harper, S. J., Ebner, M., & Creese, A. J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108445 · Cited by 3
Lozano, L. P., Jensen, R., Jennisch, M. K., Pandala, N. G., Jamshidi, F., Boldt, H. C., Tucker, B. A., & Binkley, E. M. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101359 · Cited by 3
Proteasome Inhibition Induces IRF1 Downstream Molecules Independently of JAK Activity in Cancers
Takahashi, K., Takahashi, A., Takahashi, N., Zhou, Y., Sakurai, H., & Yokoyama, S. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00006 · Cited by 3
Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8
Koch, E. A. T., Liguori, R., Castro, A. A., Schliep, S., Petzold, A., Wessely, A., Fröhlich, W., Ferrazzi, F., Vera, J., Eckstein, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209964 · Cited by 3
Sinclair, A., Krämer, S., Reinhart, C., Stehle, J., Schuster, S., Herz, T., Al-Hasani, H., Hamde, P., Selinger, O., & Birkenfeld, J. (2025) · mAbs · doi:10.1080/19420862.2025.2601360 · Cited by 3
Vascular Lakes in Uveal Melanoma and Their Association With Outcome
Jones, H., Kalirai, H., Taktak, A. F. G., Chen, K., & Coupland, S. E. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.3.32 · Cited by 3
Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency
Chabot, T., Némati, F., Herbette, A., Demeyer, A., Dayot, S., Ganier, O., Alsafadi, S., Gardrat, S., Mariani, P., Luporsi, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00326-z · Cited by 3
Self-citationHoffmann, F., Fröhlich, A., Sirokay, J. D., de Vos, L., Zarbl, R., Dietrich, J., Strieth, S., Landsberg, J., & Dietrich, D. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000879 · Cited by 3
Ugurel, S., & Gutzmer, R. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15053 · Cited by 3
Functional assay for assessment of pathogenicity of BAP1 variants
Repo, P. E., Backlund, M., Kivelä, T., & Turunen, J. A. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad193 · Cited by 3
Pharmacist perspectives on emerging T cell–engaging bispecific therapies in cancer therapeutics
Moore, D. C., Digiantonio, N., Oxencis, C. J., & Taucher, K. D. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae050 · Cited by 3
Tong, T. M. L., Fiocco, M. F., Vreugd, J. J. V. D.-D., Lutjeboer, J., Speetjens, F. M., Tijl, F. G. J., Sitsen, M. E., Zoethout, R. W. M., Martini, C. H., Vahrmeijer, A. L., et al. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03713-0 · Cited by 3
Unlocking the Promise of Antitumor Hyperthermia‐Immunotherapy with Spiky Surface Topology
Yang, M., Yu, Y., Ge, T., Zhu, Q., Zhuang, A., Wang, W., & Fan, X. (2025) · Advanced Science · doi:10.1002/advs.202415868 · Cited by 3
Nell, R. J., Zoutman, W. H., Calbet‐Llopart, N., García‐Herrera, A., Menger, N. V., Versluis, M., Puig, S., Gruis, N. A., & van der Velden, P. A. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.10.007 · Cited by 3
Sundaramurthi, H., Giricz, Z., & Kennedy, B. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169378 · Cited by 3
Einloth, K. R., Gayfield, S., McMaster, T., Didier, A. J., Dworkin, L. D., & Creeden, J. F. (2023) · Bioimpacts · doi:10.34172/bi.2023.27521 · Cited by 3
Ou, Y., Liu, M., Zhan, K., Wu, W., Huang, J., Sun, H., Zheng, H., Yu, X., Gong, H., Han, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.12.511904 · Cited by 3
Editorial: Non-cutaneous melanoma: new therapeutic insights
Rossi, E., & Carvajal, R. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1362238 · Cited by 3
Self-citationMaslov, A. A., Trageser, N. H., Kichina, J. V., Elamir, H., Gardner, E., Teaman, F., Vishwanath, V., Dugas, S. M., Heid, J., Maslov, A. Y., et al. (2025) · Biomolecules · doi:10.3390/biom15101425 · Cited by 2
Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion
Padia, S. A., Modi, S., Wehrenberg-Klee, E. P., Adamo, R. D., Ahmed, A. F., Orloff, M. M., Helmerhorst, H. J. F., Chmielowski, B., Ozkan, O. S., Burgmans, M. C., et al. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.10.018 · Cited by 2
Self-citationKrossa, I., Pisibon, C., Chéli, Y., Bille, K., Dalmasso, M., Hamadat, S., Husser, C., Irondelle, M., Cherfils‐Vicini, J., Soysouvanh, F., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08084-z · Cited by 2
Reiner, C. M., Schneider, M. A., Weilert, H., Welcker, K., Hoedtke, J., Mahnken, A. H., Stang, A., & Brüning, R. (2025) · Cancers · doi:10.3390/cancers17233834 · Cited by 2
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., Ejaz, A. M., Richtig, E., Ochsenreither, S., Reddy, S. A., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06291-x · Cited by 2
Self-citationMetastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus
Alban, J., Bowen, R. C., Reichstein, D. A., McKean, M. A., Lutzky, J., Weis, E., Carvajal, R. D., Dulka, S., Morse, B. G., Butler, M. O., et al. (2025) · Cancers · doi:10.3390/cancers18010121 · Cited by 2
Self-citationSingh, L., Kumar, N., Supriya, M., Kashyap, S., Sawant, A., Sen, S., Chawla, B. V., Lomi, N., Bakhshi, S., Nag, T. C., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02205-x · Cited by 2
The path forward for T cell engagers in patients with prostate cancer
Subudhi, S. K., Siddiqui, B. A., Zarrabi, K. K., Kelly, W. K., & Drake, C. G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013905 · Cited by 2
Advancing immunotherapy via multiple immune cells co-engagement
Li, H., Zhang, Y., Wei, Q., Sun, Q., Lin, F., & Chen, P. R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783276 · Cited by 2
Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges
Rotte, A., Sopjani, M., & Bhandaru, M. (2026) · Biomedicines · doi:10.3390/biomedicines14030654 · Cited by 2
Postow, M. A., Zang, P. D., Pal, S. K., Mauguen, A., Farwell, M. D., Gordon, M. S., Hays, D., Wong, J. Y. C., Chen, D. L., Ulaner, G. A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012208 · Cited by 2
Self-citationBeta cell–targeted PD-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices
Becker, M. W., Brown, M. E., Wiseman, K., Chiodetti, A. L., Huber, M. K., Cuaycal, A. E., Sintara, P., Ferreira, S. M., Smurlick, D., Barra, J. M., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec9029 · Cited by 2
Augustin, A., Avignon, B., Boetsch, C., Breous-Nystrom, E., Broders, O., Cabon, L., Dernick, K., Durr, E., Eigenmann, M. J., Fischer, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736584 · Cited by 2
Cohen, J. E., Mehmi, I., Avner, M., Moyers, J., & Hamid, O. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2675068 · Cited by 2
Self-citationT-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives
Muthughavi, K., Khokhar, M., Jha, H. C., & Pandey, R. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755512 · Cited by 2
Yevdash, J. I., Robinson, D., Moore, R., Li, Z., Campbell-Hanson, K. R., Gutelius, D., Moore, S. P. G., Friend, D., O'Toole, I., Harman, B. E., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5299 · Cited by 2
Carlino, M. S., Kapiteijn, E., Piperno-Neumann, S., Sullivan, R. J., Carvajal, R. D., Dummer, R., Gromke, T., Hassel, J. C., Kee, D., Ramelyte, E., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04518-z · Cited by 2
Self-citationAktuelle Behandlung des fortgeschrittenen Melanoms
Gutzmer, R., Angela, Y., & Alter, M. (2022) · Der Onkologe · doi:10.1007/s00761-022-01108-9 · Cited by 2
Lambertini, M., Comito, F., Melotti, B., Baracca, M. F., & Dika, E. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18625 · Cited by 2
Vanaken, L., Woei-A-Jin, F. J. S. H., Ginderdeuren, R. V., Deroose, C. M., Laenen, A., Missotten, G. S., Thal, D. R., Bechter, O. E., Schöffski, P., & Clément, P. M. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2211206 · Cited by 2
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
Zhang, Y., Shen, N., Jiang, A., Zhao, J., Sang, Y., Wang, A., Shen, W., & Gao, Y. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2318656 · Cited by 2
Lee, D. Y., McNamara, M., Yang, A., Yaskolko, M., Kluger, H. M., Tran, T. B., Olino, K. L., Clune, J. E., Sznol, M., & Ishizuka, J. J. (2024) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13188 · Cited by 2
Zhang, L., Pan, H., Yao, Y., Gu, X., Ge, T., Cui, J., Chai, P., Xu, X., Jia, R., Zhuang, A., et al. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2024.100108 · Cited by 2
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
